Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.
15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a metabolic antagonist of COX-2, catalyzing the degradation of inflammation mediator prostaglandin E2 (PGE2) and other prostanoids. Recent studies have established the 15-PGDH gene as a colon cancer suppressor.We evaluated 15-PDGH as a colon cancer...
Main Authors: | Cheryl L Thompson, Stephen P Fink, James D Lutterbaugh, Robert C Elston, Martina L Veigl, Sanford D Markowitz, Li Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3661460?pdf=render |
Similar Items
-
15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
by: Byeong Woo Kim, et al.
Published: (2021-01-01) -
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue
by: Dong-Hoon Yang, et al.
Published: (2017-01-01) -
15-Hydroxyprostaglandin Dehydrogenase Is a Predictor of Stroke-Associated Pneumonia
by: Yunfei Xu, et al.
Published: (2022-05-01) -
Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
by: Jee Eun Yang, et al.
Published: (2014-03-01) -
Inhibition of 15‐hydroxyprostaglandin dehydrogenase protects neurons from ferroptosis in ischemic stroke
by: Yunfei Xu, et al.
Published: (2024-01-01)